ライフサイエンスコーパス: oral candidiasis

1 ete deficiency in the neutrophil response to oral candidiasis.

2 abrata are predominant fungi associated with oral candidiasis.

3 ed attenuated virulence in a murine model of oral candidiasis.

4 ather than IL-22 is vital in defense against oral candidiasis.

5 bited potent activity in two mouse models of oral candidiasis.

6 d have promise as therapeutic agents against oral candidiasis.

7 promise as therapeutic agents in humans with oral candidiasis.

8 naling hub mediating mucosal defense against oral candidiasis.

9 burning and dysgeusia are common symptoms of oral candidiasis.

10 f human innate immune response in preventing oral candidiasis.

11 e essential for mucosal host defense against oral candidiasis," a pivotal article written by H.

12 ut was associated with a higher frequency of oral candidiasis and diarrhea.

13 s infection and diarrhoea in BE HEARD I, and oral candidiasis and headache in BE HEARD II.

14 roup had opportunistic infections (excluding oral candidiasis and tuberculosis).

15 roviral therapy for the incident outcomes of oral candidiasis and vaginal colonization.

16 Dry mouth, oral candidiasis, and recurrent aphthous ulcers are 3 of

17 Dry mouth, oral candidiasis, and recurrent aphthous ulcers are comm

18 ogues for dry mouth, topical antifungals for oral candidiasis, and topical corticosteroids for aphtho

19 Although disseminated, vaginal, and oral candidiasis are all caused by C. albicans species,

20 n 11.5% (95% CI, 3.6% to 27%) higher risk of oral candidiasis, based on a meta-analysis of 6 observat

21 18% to 28%), placing individuals at risk of oral candidiasis, dental caries, dysgeusia, masticatory/

22 The most common form of oral candidiasis, denture-associated stomatitis, involve

23 -candidiasis-ectodermal dystrophy-associated oral candidiasis, even with intact IL-17 responses.

24 stic fungal pathogen that has been linked to oral candidiasis in AIDS patients, although it has recen

25 lbicans and that is commonly associated with oral candidiasis in human immunodeficiency virus-positiv

26 Common risk factors associated with oral candidiasis include use of antibiotics (P = .04) an

27 yte infections (IR, 0.88; 0.67-1.14), and 52 oral candidiasis (IR, 0.93; 95% CI, 0.70-1.22).

28 5-2.1; P jeroveci, IR, 1.3; 95% CI, 1.1-1.6; oral candidiasis, IR, 1.2; 95% CI, 1.0-1.5; cytomegalovi

29 Oral candidiasis is an opportunistic fungal infection ca

30 The prevalence of oral candidiasis is higher in patients who are immunosup

31 ed findings from this study demonstrate that oral candidiasis may constitute a risk factor for dissem

32 and CXCL9 levels, and remission of alopecia, oral candidiasis, nail dystrophy, gastritis, enteritis,

33 ophil functions and which has been linked to oral candidiasis (OC), the most prevalent oral lesion in

34 Four cases of mild to moderate oral candidiasis occurred (60 mg = 2.4%; 120 mg = 2.1%).

35 Oral candidiasis occurred more often with bimekizumab (7

36 next 12-18 months, and patients with either oral candidiasis or hairy leukoplakia and a low CD4:CD8

37 as side effects of blocking these cytokines (oral candidiasis or tuberculosis).

38 on sequencing to analyze 43 isolates from 11 oral candidiasis patients.

39 except for tuberculosis, and was largest for oral candidiasis, Pneumocystis pneumonia, and toxoplasmo

40 eveloped to investigate whether the onset of oral candidiasis predisposes the host to secondary staph

41 over 16 and 48 weeks but was associated with oral candidiasis (predominantly mild or moderate as reco

42 mab were upper respiratory tract infections, oral candidiasis (predominantly mild or moderate as reco

43 ults suggest that HIV-infected patients with oral candidiasis should be carefully monitored for subse

44 tease Sap6 is important for virulence during oral candidiasis since it degrades host tissues to relea

45 Oral candidiasis specifically, characterized by hyphal i

46 The findings demonstrated that in mice with oral candidiasis, subsequent exposure to S. aureus resul

47 s for HIV-seropositive women was greater for oral candidiasis than for vaginal candidiasis.

48 Although DS is the most prevalent form of oral candidiasis, there are currently no feasible therap

49 ough IL-17, confers the dominant response to oral candidiasis through neutrophils and antimicrobial f

50 The markers compared were oral candidiasis (thrush) or fever; serum neopterin leve

51 patients, summary risk was highest (>5%) for oral candidiasis, tuberculosis, herpes zoster, and bacte

52 species of yeast isolated from patients with oral candidiasis, which is frequently a symptom of human

53 f adverse effects (except for an increase in oral candidiasis with FSC and F) was similar among the t